Obermatt
See Similar Stocks →

Arvinas

NSQ:ARVN · US04335A1051
PharmaceuticalsSmall

360

16
EV / EBIT100
Price / Owner Earnings55
Owner Earnings Yield1
Dividend Yield1
Price/Sales80
Price/Book56
Return on Capital13
Cash Return on Capital6
Return on Equity21
EBIT Margin1
Gross Profitability28
Accruals93
Owner Earnings Margin11
Sales growth16
Profit growth22
Reinvestment66
Price momentum32
Debt load48
Refinancing6
Debt Payback1
Liquidity37
Analyst ratings15
Opinion Changes25
Price Target Upside69
Market mood60
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Arvinas doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2014
Employees278
Websitearvinas.com
ISINUS04335A1051
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
GeneticsChronic DiseasesHematologyNeurologyImmunologyInflammationCentral Nervous SystemNeuroscienceOncologyBiotechnologyHealth CarePharmaceuticalTherapeutics

Description

Arvinas, Inc.(‘Arvinas’) operates as a clinical-stage biotechnology company. The company is dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through the company’s PROteolysis TArgeting Chimera,…

Analysis

Weak and unloved

Arvinas, Inc. scores below average on quality and is priced accordingly, a low-conviction position in either direction.

Valuation data is not available for this company.

Growth is tepid; the safety picture is adequate. The company scores 0/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
12
2023202420252026

All-time high

63

Jan 2025

All-time low

4

Mar 2026

Average rank

35

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
80
35
11
9
Price/Earnings
39
29
29
2
Price/Book
56
58
24
69
Dividend Yield
1
1
1
1
Value (overall)
73
52
14
43

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Arvinas with its peers
Nektar
NAQ:NKTR
4
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Cognition Therapeutics
NAQ:CGTX
—
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Rapport Therapeutics
NMQ:RAPP
13
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Veru
NAQ:VERU
23
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
ImageneBio
NAQ:IMA
22
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Eli Lilly
NYQ:LLY
76
CountryUSA
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →